deltatrials
Completed NA NCT01049815

Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease

A Randomized-controlled Trial Comparing the Efficacy of Two Phosphorous Binders, Renagel and Caltrate in Reducing the Rate of Progression of Femoral and Carotid IMT Thickening as Measured by B-mode Ultrasound in Dialysis Patients.

Sponsor: Genzyme, a Sanofi Company

Conditions End Stage Renal Disease Hemodialysis Intimal Media Thickness
Interventions Calcium Carbonate sevelamer hydrochloride
Updated 5 times since 2017 Last updated: Jan 13, 2010 Started: Feb 28, 2005 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

A NA clinical study on End Stage Renal Disease and Hemodialysis, this trial is completed. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Feb 2017 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genzyme, a Sanofi Company
  • Tel-Aviv Sourasky Medical Center
  • Wolfson Medical Center
Data source: Tel-Aviv Sourasky Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Holon, Israel
  • • Tel Aviv, Israel